Treiber; Hans-Jorg

Patent Applications and Registrations

Patent applications and USPTO patent grants for Treiber; Hans-Jorg.The latest application filed is for "novel substituted amides, their preparation and use".

Company Profile

0.18.8

Treiber; Hans-Jorg - Bruhl DE

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Use of dopamine D.sub.3 receptor ligands for the production of drugs for treating renal function disorders Grant 8,785,447 - Muhlbauer , et al. July 22, 2	2014-07-22
Novel Substituted Amides, Their Preparation And Use App 20110275615 - Treiber; Hans-Jorg ; et al.	2011-11-10
Substituted amides, their preparation and use Grant 7,956,093 - Lubisch , et al. June 7, 2	2011-06-07
Triazole compounds and the therapeutic use thereof Grant 7,465,744 - Starck , et al. December 16, 2	2008-12-16
Novel substituted amides, their preparation and use App 20080113989 - Lubisch; Wilfried ; et al.	2008-05-15
Substituted amides, their preparation and use Grant 7,276,500 - Lubisch , et al. October 2, 2	2007-10-02
Use Of Dopamine D3 Receptor Ligands For The Production Of Drugs For Treating Renal Function Disorders App 20060223793 - Muhlbauer; Bernd ; et al.	2006-10-05
Dopamine D.sub.3 receptor ligands or antagonists for use in the treatment of renal function disorders Grant 7,098,214 - Muhlbauer , et al. August 29, 2	2006-08-29
Substituted amides, their preparation and use Grant 6,753,327 - Lubisch , et al. June 22, 2	2004-06-22
Novel heterocyclically substituted amides, their preparation and use App 20040097508 - Lubisch, Wilfried ; et al.	2004-05-20
Novel substituted amides, their preparation and use App 20040082569 - Lubisch, Wilfried ; et al.	2004-04-29
Heterocyclically substituted amides, their preparation and use Grant 6,630,493 - Lubisch , et al. October 7, 2	2003-10-07
Triazole compounds with dopamine-D3-receptor affinity Grant 6,602,867 - Starck , et al. August 5, 2	2003-08-05
Heterocyclically substituted amides used as calpain inhibitors Grant 6,562,827 - Lubisch , et al. May 13, 2	2003-05-13
Use of dopamine-d3 receptor ligands for the treatment of diseases of the central nervous system App 20030087917 - Strack, Dorothea ; et al.	2003-05-08
Heterocyclically substituted amides, their production and their use Grant 6,482,832 - Lubisch , et al. November 19, 2	2002-11-19
Triazole compounds and the use thereof as dopamine-D3 -ligands Grant 6,472,392 - Starck , et al. October 29, 2	2002-10-29
2-{3-[4-(2-T-butyl-6-trifluoromethyl-4-pyrimidinyl)-1- piperazinyl] propylthio}-4-pyrimidinol fumarate App 20020143179 - Hoger, Thomas ; et al.	2002-10-03
Substituted amides, their production and their use Grant 6,448,254 - Lubisch , et al. September 10, 2	2002-09-10
Substituted benzamides, their production and their use as cysteine protease inhibitors Grant 6,436,925 - Lubisch , et al. August 20, 2	2002-08-20
2{3-[4-(2-t-butyl-6-trifluoromethylpyridin-4-yl) Piperazin-1-yl] Propylmercapto} Pyrimidin-4-ol-fumarate App 20010020022 - BLANK, STEFAN ; et al.	2001-09-06
Substituted aza and diazacycloheptane and cyclooctane compounds and their use Grant 6,214,822 - Treiber , et al. April 10, 2	2001-04-10
Heterocyclically substituted benzamides and their use in fighting diseases Grant 6,172,072 - Lubisch , et al. January 9, 2	2001-01-09
Ketobenzamides as calpain inhibitors Grant 6,103,720 - Lubisch , et al. August 15, 2	2000-08-15
Trifluoromethyl-substituted phenyl acetonitriles Grant 3,957,845 - Treiber , et al. May 18, 1	1976-05-18

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.